Dopaminergic modulation of the reward system in schizophrenia: A placebo-controlled dopamine depletion fMRI study

European Neuropsychopharmacology

Volumn 23, Issue 11, 2013, Pages 1577-1586

  da Silva Alves, Fabiana ^a   Bakker, Geor ^c   Schmitz, Nicole ^a   Abeling, Nico ^a   Hasler, Gregor ^b   van der Meer, Johan ^a   Nederveen, Aart ^a   de Haan, Lieuwe ^a   Linszen, Don ^a   van Amelsvoort, Therese ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

AMPT; Brain; Dopamine; Reward; Schizophrenia; Striatum

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID; METIROSINE; PROLACTIN;

ADULT; ANTICIPATION; ARTICLE; BOLD SIGNAL; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE URINE LEVEL; DOPAMINERGIC TRANSMISSION; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; NEUROMODULATION; NUCLEAR MAGNETIC RESONANCE SCANNER; POSTERIOR CINGULATE; PRIORITY JOURNAL; REWARD; SCHIZOPHRENIA; STIMULUS; SUPERIOR TEMPORAL GYRUS;

AMPT; BRAIN; DOPAMINE; REWARD; SCHIZOPHRENIA; STRIATUM;

ADULT; ALPHA-METHYLTYROSINE; ANTICIPATION, PSYCHOLOGICAL; BRAIN; BRAIN MAPPING; DOPAMINE; DOUBLE-BLIND METHOD; HOMOVANILLIC ACID; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PLACEBOS; PROLACTIN; PSYCHOMOTOR PERFORMANCE; REWARD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84886798328     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.06.008     Document Type: Article

References (44)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. International J. Neuropsychopharmacol. 2004, 7(Suppl. 1):S1-S5.
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., Weiss R., Cooper T.B., Mann J.J., Van Heertum R.L., Gorman J.M., Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 2000, 97:8104-8109.
3. Abler B., Erk S., Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology (Berlin) 2007, 191:823-833.
4. Aron A.R., Fletcher P.C., Bullmore E.T., Sahakian B.J., Robbins T.W. Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat. Neurosci. 2003, 6:115-116.
5. Backman L., Nyberg L., Lindenberger U., Li S.C., Farde L. The correlative triad among aging, dopamine, and cognition: current status and future prospects. Neurosci. Biobehav. Rev. 2006, 30:791-807.
6. Bjork J.M., Knutson B., Fong G.W., Caggiano D.M., Bennett S.M., Hommer D.W. Incentive-elicited brain activation in adolescents: similarities and differences from young adults. J. Neurosci. 2004, 24:1793-1802.
7. Bjorklund A., Dunnett S.B. Fifty years of dopamine research. Trends Neurosci. 2007, 30:185-187.
8. Boot E., Booij J., Hasler G., Zinkstok J.R., de H.L., Linszen D.H., van Amelsvoort T.A. AMPT-induced monoamine depletion in humans: evaluation of two alternative [(123)I]IBZM SPECT procedures. Eur. J. Nucl. Med. Mol. Imag. 2008, 35:1350-1356.
9. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R., Flanagan R.J., Ell P.J., Pilowsky L.S. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am. J. Psychiatry 2003, 160:1413-1420.
10. Brett M., Johnsrude I.S., Owen A.M. The problem of functional localization in the human brain. Nat. Rev. Neurosci. 2002, 3:243-249.
11. Canavan A.G.M., Dunn G., McMillan T.M. Principal components of the WAIS-R. Br. J. Clin. Psychol. 1986, 25:81-86.
12. Carter C.S., Mintun M., Cohen J.D. Interference and facilitation effects during selective attention: an H215O PET study of Stroop task performance. NeuroImage 1995, 2:264-272.
13. Cohen M.X., Bour L., Mantione M., Figee M., Vink M., Tijssen M.A., van Rootselaar A.F., van den Munckhof P., Schuurman P.R., Denys D. Top-down-directed synchrony from medial frontal cortex to nucleus accumbens during reward anticipation. Hum. Brain. Mapp. 2012, 33:246-252.
14. da Silva Alves F., Schmitz N., Figee M., Abeling N., Hasler G., van der Meer J., Nederveen A., de H.L., Linszen D., van A.T. Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. J. Psychopharmacol. 2011, 25:538-549.
15. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148:1474-1486.
16. de Haan L., Weisfelt M., Dingemans P.M., Linszen D.H., Wouters L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology (Berlin) 2002, 162:24-28.
17. Desmond J.E., Glover G.H. Estimating sample size in functional MRI (fMRI) neuroimaging studies: statistical power analyses. J. Neurosci. Methods 2002, 118:115-128.
18. Friston K.J., Frith C.D., Turner R., Frackowiak R.S. Characterizing evoked hemodynamics with fMRI. Neuroimage 1995, 2:157-165.
19. Gold J.M., Waltz J.A., Prentice K.J., Morris S.E., Heerey E.A. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr. Bull. 2008, 34:835-847.
20. Hasler G., Luckenbaugh D.A., Snow J., Meyers N., Waldeck T., Geraci M., Roiser J., Knutson B., Charney D.S., Drevets W.C. Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder. Biol. Psychiatry 2009, 66:201-205.
21. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr. Bull. 2010, 36:472-485.
22. Juckel G., Friedel E., Koslowski M., Witthaus H., Ozgurdal S., Gudlowski Y., Knutson B., Wrase J., Brune M., Heinz A., Schlagenhauf F. Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia. Neuropsychobiology 2012, 66:50-56.
23. Juckel G., Schlagenhauf F., Koslowski M., Filonov D., Wustenberg T., Villringer A., Knutson B., Kienast T., Gallinat J., Wrase J., Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berlin) 2006, 187:222-228.
24. Juckel G., Schlagenhauf F., Koslowski M., Wustenberg T., Villringer A., Knutson B., Wrase J., Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409-416.
25. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
26. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
27. Knutson B., Adams C.M., Fong G.W., Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J. Neurosci. 2001, 21:RC159.
28. Knutson B., Bjork J.M., Fong G.W., Hommer D., Mattay V.S., Weinberger D.R. Amphetamine modulates human incentive processing. Neuron 2004, 43:261-269.
29. Knutson B., Fong G.W., Adams C.M., Varner J.L., Hommer D. Dissociation of reward anticipation and outcome with event-related fMRI. NeuroReport 2001, 12:3683-3687.
30. Menon M., Jensen J., Vitcu I., Graff-Guerrero A., Crawley A., Smith M.A., Kapur S. Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biol. Psychiatry 2007, 62:765-772.
31. Mogenson G.J., Jones D.L., Yim C.Y. From motivation to action: functional interface between the limbic system and the motor system. Prog. Neurobiol. 1980, 14:69-97.
32. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):133-138.
33. Ridderinkhof K.R., Ullsperger M., Crone E.A., Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 2004, 306:443-447.
34. Samanez-Larkin G.R., Gibbs S.E., Khanna K., Nielsen L., Carstensen L.L., Knutson B. Anticipation of monetary gain but not loss in healthy older adults. Nat. Neurosci. 2007, 10:787-791.
35. Schlagenhauf F., Juckel G., Koslowski M., Kahnt T., Knutson B., Dembler T., Kienast T., Gallinat J., Wrase J., Heinz A. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berlin) 2008, 196:673-684.
36. Schott B.H., Niehaus L., Wittmann B.C., Schutze H., Seidenbecher C.I., Heinze H.J., Duzel E. Ageing and early-stage Parkinson's disease affect separable neural mechanisms of mesolimbic reward processing. Brain 2007, 130:2412-2424.
37. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 2002, 47:27-38.
38. Simon J.J., Biller A., Walther S., Roesch-Ely D., Stippich C., Weisbrod M., Kaiser S. Neural correlates of reward processing in schizophrenia-relationship to apathy and depression. Schizophr. Res. 2010, 118:154-161.
39. Uchida H., Takeuchi H., Graff- Guerrero A., Suzuki T., Wantanabe K., Mamo D.c. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J. Clin. Psychopharmacol. 2011, 31(3):318-325.
40. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
41. Walter H., Kammerer H., Frasch K., Spitzer M., Abler B. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. Psychopharmacology (Berlin) 2009, 206:121-132.
42. Waltz J.A., Schweitzer J.B., Ross T.J., Kurup P.K., Salmeron B.J., Rose E.J., Gold J.M., Stein E.A. Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia. Neuropsychopharmacology 2010, 35:2427-2439.
43. Wechsler D. WAIS-III: Wechsler Adult Intelligence Scale. Administration and Scoring Manual 1997, Psychological Corporation, San Antonio, TX.
44. Ziauddeen H., Murray G.K. The relevance of reward pathways for schizophrenia. Curr. Opin. Psychiatry 2010, 23:91-96.